Vol. 150, No. 3 — January 16, 2016

GOVERNMENT NOTICES

DEPARTMENT OF EMPLOYMENT AND SOCIAL DEVELOPMENT

CANADA STUDENT LOANS REGULATIONS

Interest rates

In accordance with subsection 13(3) of the Canada Student Loans Regulations, notice is hereby given that, pursuant to subsections 13(1) and 13(2) respectively, the Minister of Employment, Workforce Development and Labour has fixed the Class “A” rate of interest at 1.625% and the Class “B” rate of interest at 2.250% for the loan year beginning on August 1, 2015, and ending on July 31, 2016.

December 28, 2015

THE HONOURABLE MARYANN MIHYCHUK, P.C., M.P.
Minister of Labour styled as Minister of Employment,
Workforce Development and Labour

[3-1-o]

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant material safety data sheet (MSDS) and (where applicable) the label listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 4th Floor, Ottawa, Ontario K1A 0K9.

ROSSLYNN MILLER-LEE
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015 and the former legislation (HPA/CPR) is referred to as WHMIS 1988.

Transitional provisions allow compliance with either WHMIS 1988 or WHMIS 2015 for a specified period of time. All claims for exemption in this publication were filed and evaluated in accordance with the provisions of WHMIS 1988.

There were no written representations from affected parties with respect to any of the claims for exemption and related MSDSs or labels mentioned below.

Each of the claims for exemption listed in the table below was found to be valid except for those for Registry Numbers (RNs) 9054, 9056, 9070, 9080, 9140, 9189, 9213, 9219, 9246, 9309, 9364, 9366, 9374, 9400, 9401, 9421 and 9505, which were found to be partially valid, and RN 9137, which was found to be invalid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

Claimant Product Identifier RN Date of Decision
Cansolv Technologies Inc. Cansolv™ Absorbent DC-103 Concentrate 9038 2015-07-06
DuPont Electronic Technologies - MCM BQ311 9039 2015-07-16
Schlumberger Canada Ltd. External CT Corrosion Inhibitor A265 9041 2015-06-02
Trican Well Service Ltd. WXB-16 9048 2015-06-30
Baker Petrolite Corp. CRO2032X CORROSION INHIBITOR 9049 2015-07-03
Afton Chemical Corporation Cutsol 9054 2015-06-30
Afton Chemical Corporation PETROMIX FC-M 9055 2015-06-30
Afton Chemical Corporation CUTSOL HD 9056 2015-09-10
Allnex Canada Inc., (c/o Goodmans, LLP) DESMOLUX® U 200 radiation curing resins 9060 2015-06-10
Multi-Chem Production Chemicals Co. MC MX 5-3504 9063 2015-06-30
Stepan Company AGENT 150-S24 9064 2015-06-08
Stepan Company PETROSTEP S-1 HA 9065 2015-06-05
Stepan Company AGENT 150-S23 9066 2015-06-05
Nalco Canada Co. Nalco® EC6790A 9067 2015-06-01
Calfrac Well Services Ltd. DWP-134 9070 2015-07-07
Construction DJL Inc. Polytech ET1 9073 2015-07-09
GE Water & Process Technologies Canada PROSWEET S1790 9074 2015-06-25
GE Water & Process Technologies Canada SPEC-AID 8Q206ULS 9075 2015-07-17
GE Water & Process Technologies Canada SPEC-AID 8Q213C 9076 2015-06-25
GE Water & Process Technologies Canada SPEC-AID 8Q206S ULS 9077 2015-07-16
GE Water & Process Technologies Canada SPEC-AID 8Q107ULS 9078 2015-06-18
GE Water & Process Technologies Canada SPEC-AID 8Q5151ULS 9079 2015-06-19
GE Water & Process Technologies Canada PROSWEET S-1791 9080 2015-06-19
BASF Canada Inc. TINUVIN XT 850 GRANULES 9085 2015-06-19
ECO-TEC Inc. ECO BRINE-XLH 9092 2015-07-28
Stepan Company PETROSTEP LB BLEND 9099 2015-08-28
BASF Canada Inc. Inoterra DWF 9101 2015-06-22
BASF Canada Inc. Inoterra DWF C 9102 2015-06-22
Stepan Company TOXIMUL 8363 9106 2015-06-26
Baker Petrolite Corp. TOLAD™ 9022M ADDITIVE 9107 2015-07-16
Nalco Canada Co. EC6019A WATER CLARIFIER 9116 2015-06-15
Nalco Canada Co. BREAXIT® SP396 9117 2015-06-15
Air Products & Chemicals, Inc. EnviroGem® 360 SURFACTANT 9127 2015-06-02
Air Products & Chemicals, Inc. XF-AC14003 9128 2015-06-02
Baker Petrolite Corp. PAO2358 PARAFFIN CONTROL 9130 2015-06-22
Dow Corning Corporation DOW CORNING® 3-1953 CONFORMAL COATING 9131 2015-07-23
Baker Petrolite Corp. PETROSWEET™ HSO3510 H2S SCAVENGER 9132 2015-07-03
Enthone, Inc. ANKOR® LF19 9136 2015-06-22
Enthone, Inc. ANKOR® NFDS 9137 2015-07-03
Enthone, Inc. CUPROSTAR® 1550 MAINTENANCE 9140 2015-06-01
Enthone, Inc. ENSEAL® 140 9146 2015-06-22
Enthone, Inc. ENSTRIP® GT-317A 9149 2015-06-23
Enthone, Inc. PERMA PASS® 3098 HC 9158 2015-07-03
CESI Chemical DWP-967 9171 2015-09-29
Nalco Canada Co. Comptrene® EC3420G 9180 2015-09-29
Baker Petrolite Corp. CRO2032U CORROSION INHIBITOR 9185 2015-09-23
Steve Strba Consulting Inc. SCL 809 CII 9189 2015-08-28
Rohm and Haas Canada LP ACRYLIGARD™ CS-132 RESIN POWDER 9190 2015-09-23
Halliburton Energy Services, Inc. DUAL SPACER SURFACTANT A 9199 2015-08-17
Halliburton Energy Services, Inc. DUAL SPACER SURFACTANT B 9200 2015-08-14
Calfrac Well Services Ltd. DWP-973 9201 2015-07-20
Chevron Oronite Company LLC OLOA 54000 9202 2015-08-28
Nalco Canada Co. RESOLV™ EC2630A 9203 2015-07-30
3M Canada Company 3M™ SMC/Fiberglass Repair (90 Minutes) Adhesive PN 08274 - Accelerator 9205 2015-08-17
Afton Chemical Corporation HiTEC® 12204 Performance Additive 9206 2015-09-08
3M Canada Company 3M™ Fire Barrier Rated Foam, FIP, 1-Step Part A 9208 2015-09-03
Arkema Canada Inc. LUPEROX® EZ Breaker 200G 9209 2015-08-19
Allnex Canada Inc., (c/o Goodmans, LLP) UCECOAT® 7674 radiation curing resins 9210 2015-09-18
Fluid Energy Group Ltd. Enviro-Syn HCR 2000 Series 9211 2015-08-06
Hydro Technologies (Canada) Inc. HY BRITE® RBC-1300 9212 2015-07-23
Stepan Company AGENT 4702-55 9213 2015-07-20
Momentive Performance Materials Niax® catalyst A-300 9215 2015-08-31
Canadian Energy Services EnerScav C 9218 2015-08-28
Momentive Performance Materials Niax® silicone L-580 9219 2015-07-06
Baker Petrolite Corp. PAO3086 ASPHALTENE INHIBITOR 9220 2015-09-23
Rohm and Haas Canada LP Preferred DC 9223 2015-07-16
Allnex Canada Inc., (c/o Goodmans, LLP) DESMOLUX® XP2738 radiation curing resins 9225 2015-08-27
Chevron Oronite Company LLC LUBAD 1829 9226 2015-07-09
DuPont Electronic Technologies-MCM PE826 9227 2015-06-16
Multi-Chem Production Chemicals Co. RockOn™ MX 5-2556 9229 2015-08-07
Multi-Chem Production Chemicals Co. RockOn™ MX 5-3447 9230 2015-08-07
Baker Petrolite Corp. CRONOX™ 283ES CORROSION INHIBITOR 9231 2015-09-11
Win Chemicals Ltd. CVS 9233 2015-07-20
Nalco Canada Co. EnterFast® EC9008B 9234 2015-09-21
3M Canada Company 3M™ Scotch-Weld™ Acrylic Adhesive DP8410NS Green, Part A 9235 2015-07-03
Hydro Technologies (Canada) Inc. HY BRITE® RA-1504 9237 2015-07-23
Hydro Technologies (Canada) Inc. HY BRITE® CK-1109 9238 2015-07-23
Univar Canada Ltd. ACRYSIRUP DR-460 9239 2015-09-22
Univar Canada Ltd. ACRYSIRUP 3018 A&B 9240 2015-09-22
IPAC Chemicals Ltd. Envirobind CAP 9241 2015-07-06
Univar Canada Ltd. ACRYSIRUP TW-008 9242 2015-09-22
Evonik Corporation Protectosil® CHEM-TRETE® PB 100 9243 2015-09-23
Nalco Canada Co. Nalco® OS7070 9244 2015-07-03
Momentive Performance Materials Niax® flame lamination additive FLE-200 9246 2015-07-20
Cytec Industries Inc. OREPREP® F-603 Frother 9260 2015-07-29
Afton Chemical Corporation HiTEC® 3491LV Performance Additive 9309 2015-04-08
IPAC Chemicals Ltd. Envirobind APS 9329 2015-06-10
BYK USA Inc. Disperbyk-111 9349 2015-06-29
Afton Chemical Corporation HiTEC® 5769 Performance Additive 9364 2015-07-30
Afton Chemical Corporation HiTEC® 1811 Performance Additive 9366 2015-06-19
Reichhold, Inc. BECKOSOL AQ® 305 9367 2015-06-10
Reichhold, Inc. BECKOSOL AQ® 300 9368 2015-06-10
Reichhold, Inc. BECKOSOL AQ® 205 9369 2015-06-10
Reichhold, Inc. BECKOSOL AQ® 201 9370 2015-06-10
Reichhold, Inc. BECKOSOL AQ® 101 9371 2015-06-10
3M Canada Company 3M™ Impact Resistant Structural Adhesive Part A, Pns 07333, 57333 9373 2015-07-30
Afton Chemical Corporation HiTEC® 8703G Performance Additive 9374 2015-08-26
Nalco Canada ULC DURASOFT™ 64870 9377 2015-06-19
Weatherford WSI 3308 9378 2015-06-11
Weatherford WSP 2736 9379 2015-07-03
Solvay Canada Inc. AGRHOSPEC HT 2009 9380 2015-08-18
Charles Tennant & Company (Canada) Ltd. FLEX 20 9382 2015-06-10
Charles Tennant & Company (Canada) Ltd. FLEX 31 9383 2015-06-10
Charles Tennant & Company (Canada) Ltd. FLEX 41 9384 2015-08-20
GE Water & Process Technologies Canada GENGARD GN8020 9385 2015-07-07
GE Water & Process Technologies Canada GENGARD GN8220 9386 2015-07-07
Dow Chemical Canada ULC GT Amine MDX1 9387 2015-07-16
GE Water & Process Technologies Canada GENGARD GN8221 9388 2015-07-07
GE Water & Process Technologies Canada GENGARD GN8222 9389 2015-07-07
GE Water & Process Technologies Canada GENGARD GN8224 9390 2015-07-07
GE Water & Process Technologies Canada GENGARD GN8225 9391 2015-08-25
GE Water & Process Technologies Canada GENGARD GN8240 9392 2015-08-06
Trican Well Service Ltd. AI-11 9393 2015-08-17
GE Water & Process Technologies Canada PETROFLO 20Y99 9394 2015-07-14
GE Water & Process Technologies Canada PETROFLO 20Y98 9395 2015-07-14
Nalco Canada ULC NALCO® 9729 9396 2015-08-21
Afton Chemical Corporation HiTEC® 052 Performance Additive 9397 2015-07-20
Afton Chemical Corporation HiTEC® 594 Performance Additive 9400 2015-07-13
Afton Chemical Corporation HiTEC® 596 Performance Additive 9401 2015-08-28
Afton Chemical Corporation HiTEC® 510 Performance Additive 9402 2015-07-09
GE Water & Process Technologies Canada MAX-AMINE GT-741 9404 2015-07-02
GE Water & Process Technologies Canada PHILMPLUS* 5K35 9405 2015-07-30
GE Water & Process Technologies Canada STYREX40 9406 2015-06-10
GE Water & Process Technologies Canada GENGARD GN8021 9407 2015-07-07
BWA Water Additives US LLC Belcor 585 9410 2015-08-19
The Lubrizol Corporation LUBRIZOL® 5954AIM 9411 2015-06-17
GE Water & Process Technologies Canada STYREX*50 9412 2015-07-21
GE Water & Process Technologies Canada BETZ PETROMEEN OS-23B 9414 2015-08-27
Momentive Performance Materials Silbreak* 503 demulsifier 9416 2015-06-09
Baker Petrolite LLC JETTISON™ 3000 SOLIDS RELEASE AGENT 9417 2015-06-18
Chevron Oronite Company LLC OLOA 45400E 9418 2015-07-16
MeadWestvaco Corp. Specialty Chemicals Div. EnvaMul™ 1767 9419 2015-06-10
Momentive Performance Materials Niax* flame lamination additive FLE-200LF 9421 2015-07-17
Cytec Industries Inc. BR® 624 Potting Compound 9422 2015-07-20
Cytec Industries Inc. BR® 127 NC ESD Primer 9423 2015-08-28
Chevron Oronite Company LLC LUBAD 1860 9429 2015-06-10
Nalco Canada ULC NALCO EC1436A 9434 2015-08-24
Afton Chemical Corporation Polartech BA 30 T 9448 2015-09-03
Afton Chemical Corporation Polartech MA 5715 DT 9451 2015-08-25
Baker Hughes Oilfield Operations StimCarb™ SAF fluid 9465 2015-08-25
Halliburton Energy Services, Inc. FR-68 9469 2015-08-25
Cansolv Technologies Inc. CANSOLV™ Absorbent DS 9487 2015-09-23
Nalco Canada ULC NALCO® EC3038A 9504 2015-08-24
Afton Chemical Corporation HiTEC® 2235 Performance Additive 9505 2015-09-18
Nalco Canada ULC CLAR10650A 9507 2015-08-24

The subject of the claim for exemption on which the screening officer issued a decision for the following claims is different from the subject of the claim that was published in the Notice of Filing.

RN Notice of Filing Publication Date Original Subject of the Claim Revised Subject of the Claim
9038 2014-01-25 C.i. and c. of three ingredients C.i. and c. of three ingredients, and the name of a toxicological study
9048 2014-01-25 C.i. of one ingredient C.i. and c. of one ingredient
9056 2014-01-25 C.i. of four ingredients C.i. and c. of five ingredients
9085 2014-01-25 C.i. of one ingredient C.i. and c. of one ingredient
9099 2014-04-26 C.i. of three ingredients C.i. and c. of four ingredients
9136 2014-04-26 C.i. and c. of one ingredient C.i. and c. of one ingredient, c. of one ingredient
9171 2014-04-26 C.i. of four ingredients C.i. and c. of five ingredients
9180 2014-04-26 C.i. of two ingredients C.i. and c. of two ingredients, c. of three ingredients
9185 2014-04-26 C.i. of five ingredients C.i. and c. of five ingredients
9203 2014-07-19 C.i. of one ingredient C.i. and c. of one ingredient, c. of two ingredients
9206 2014-07-19 C.i. of four ingredients C.i. and c. of three ingredients
9208 2014-07-19 C.i. of three ingredients C.i. of four ingredients
9209 2014-07-19 C.i. of one ingredient C.i. and c. of one ingredient
9211 2014-07-19 C.i. of one ingredient C.i. and c. of one ingredient
9215 2014-07-19 C.i. of one ingredient C.i. and c. of one ingredient, c. of one ingredient
9218 2014-07-19 C.i. of one ingredient C.i. and c. of one ingredient
9219 2014-07-19 C.i. of three ingredients C.i. and c. of three ingredients
9223 2014-07-19 C.i. of two ingredients C.i. and c. of two ingredients
9227 2014-07-19 C.i. of one ingredient C.i. and c. of one ingredient, c. of five ingredients
9229 2014-07-19 C.i. of three ingredients C.i. and c. of two ingredients, c. of one ingredient
9230 2014-07-19 C.i. of two ingredients C.i. and c. of three ingredients, c. of one ingredient
9239 2014-07-19

C.i. and c. of two ingredients

C.i. and c. of three ingredients
9240 2014-07-19 C.i. and c. of two ingredients C.i. and c. of three ingredients
9242 2014-07-19 C.i. and c. of two ingredients C.i. and c. of three ingredients
9309 2015-01-31 C.i. of nine ingredients C.i. and c. of nine ingredients
9329 2015-01-31 C.i. and c. of one ingredient C.i. and c. of seven ingredients
9349 2015-01-31 C.i. of one ingredient C.i. and c. of one ingredient, c. of one ingredient
9364 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients
9366 2015-04-25 C.i. of six ingredients C.i. and c. of six ingredients
9367 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients
9368 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients
9369 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients
9370 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients
9371 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients
9373 2015-04-25 C.i. of two ingredients C.i. of three ingredients, c.i. and c. of one ingredient, c. of one ingredient
9374 2015-04-25 C.i. of four ingredients C.i. and c. of seven ingredients
9378 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient, c. of three ingredients
9379 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient, c. of three ingredients
9397 2015-04-25 C.i. of one ingredient C.i. and c. of two ingredients
9400 2015-04-25 C.i. of five ingredients C.i. and c. of five ingredients
9401 2015-04-25 C.i. of three ingredients C.i. and c. of five ingredients
9410 2015-04-25 C.i. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9411 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient
9421 2015-04-25 C.i. of three ingredients C.i. and c. of three ingredients
9422 2015-04-25 C.i. of four ingredients C.i. and c. of four ingredients
9423 2015-04-25 C.i. of three ingredients C.i. and c. of three ingredients, c. of five ingredients
9434 2015-04-25 C.i. of one ingredient C.i. of two ingredients
9435 2015-04-25 C.i. of one ingredient C.i. and c. of two ingredients
9436 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient, c. of four ingredients
9439 2015-04-25 C.i. of one ingredient C.i. and c. of one ingredient, c. of four ingredients
9468 2015-07-25 C.i. and c. of one ingredient C.i. and c. of one ingredient, c. of two ingredients
9469 2015-07-25 C.i. and c. of three ingredients C.i. and c. of four ingredients
9481 2015-07-25 C.i. and c. of two ingredients C.i. and c. of two ingredients, c. of one ingredient
9504 2015-07-25 C.i. and c. of five ingredients C.i. and c. of four ingredients
9505 2015-07-25 C.i. and c. of two ingredients, c. of one ingredient C.i. and c. of four ingredients

Note: C.i. = Chemical identity and c. = concentration.

Having regard for the various data readily available in the literature and any information provided by the claimant, the screening officer found that only the respective MSDSs in respect of the claims bearing RNs 9064, 9065, 9066, 9085, 9190, 9212, 9215, 9227, 9235, 9237, 9238, 9349, 9396, 9416, 9417, 9419, 9429, 9448 and 9507 complied with the requirements of the relevant legislation.

In all cases where the MSDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the MSDS or the label amended as necessary.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant MSDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.

RN: 9038 Date: 2015-08-07

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause teratogenic and embryotoxic effects.
  2. Disclose an LD50 (rat, oral) value of >2 000 mg/kg for the confidential ingredient “cyclic amine (1)”.
  3. Disclose an LD50 (rat, oral) value of >2 000 mg/kg for the confidential ingredient “cyclic amine (2)”.
  4. Disclose an LD50 (rabbit, dermal) value of >2 000 mg/kg for the confidential ingredient “cyclic amine (2)”.

RN: 9039 Date: 2015-08-04

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an ACGIH TLV–TWA exposure limit of 0.05 mg/m3 for the ingredient “lead”.
  2. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.

RN: 9041 Date: 2015-07-07

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentrations of the ingredients in the product.
  2. Disclose that an ingredient has been shown to be an eye irritant.

RN: 9048 Date: 2015-06-30

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D2A and E.
  2. Disclose the additional WHMIS E pictogram, if WHMIS pictograms are shown on the MSDS.
  3. Disclose that an ingredient has been shown to cause eye and skin corrosion in laboratory animals.
  4. Disclose the ACGIH–TWA exposure limit of 2 mg/m3 for the confidential ingredients “borate salts” and “inorganic metal oxide” and the ACGIH–STEL exposure limit of 6 mg/m3 for the confidential ingredient “borate salts”.
  5. Disclose water and ethanol as incompatible materials.
  6. Disclose that an ingredient has been shown to cause reproductive toxicity in the absence of maternal toxicity.
  7. Disclose that an ingredient has been shown to cause teratogenic effects in the absence of maternal toxicity.

RN: 9049 Date: 2015-07-31

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose ingestion as an additional route of entry.

RN: 9060 Date: 2015-07-13

The claimant had been advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” and “oxides of nitrogen” to the list of hazardous decomposition products.

RN: 9063 Date: 2015-08-11

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9067 Date: 2015-07-06

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9073 Date: 2015-07-20

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 4 320 mg/kg for the confidential ingredient « heavy, complex hydrocarbons ».
  2. Disclose that an ingredient in the product has been shown to cause teratogenic effects.
  3. Disclose that an ingredient in the product has been shown to cause mutagenic effects, in vitro.
  4. Disclose that an ingredient in the product has been shown to cause harmful effects on the liver.

RN: 9074 Date: 2015-07-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause liver effects in laboratory animals.
  2. Disclose an LD50 (rat, oral) value of >5 000 mg/kg for the confidential ingredient “glycol ether”.
  3. Disclose an LD50 (rabbit, dermal) value of >5 000 mg/kg for the confidential ingredient “glycol ether”.

RN: 9075 Date: 2015-08-17

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin and eye corrosion in laboratory animals.
  2. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  3. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “substituted phenol”.
  4. Disclose an acceptable LD50 (rat, oral) value for an additional ingredient.
  5. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class E.

RN: 9076 Date: 2015-07-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 222 mg/kg for the ingredient “N,N′-di-sec-butyl-p-phenylenediamine”.
  2. Disclose an LD50 (rat, oral) value of 8 697 mg/kg for the confidential ingredient “substituted phenol”.

RN: 9077 Date: 2015-08-12

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the product has been shown to cause skin and eye corrosion in animals.
  2. Disclose that acute exposure to an ingredient has caused central nervous system effects, liver effects, kidney effects and immune system effects in laboratory animals.
  3. Disclose adequate measures to be taken in case of a spill or leak.
  4. Disclose adequate measures for handling, equipment, and storage.
  5. Disclose the ACGIH “skin” notation for the ingredient “phenol”.
  6. Disclose an LD50 (rabbit, dermal) value of 0.625 mL/kg for the ingredient “phenol”.
  7. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.
  8. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1B and E.

RN: 9078 Date: 2015-07-16

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the ACGIH “skin” notation for the confidential ingredients “alkyl amine” and “ethylene diamine”.
  2. Disclose an LD50 (rabbit, dermal) value of 1 128 mg/kg for the product.
  3. Disclose an LD50 (rat, oral) value of >500 mg/kg for the confidential ingredient “alkyl amine”.

RN: 9079 Date: 2015-07-16

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the product has been shown to cause teratogenic effects.
  2. Disclose that an ingredient in the product has been shown to cause skin and eye corrosion in animals.
  3. Disclose an LD50 (rat, oral) value of 1 443 mg/kg for the product.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D2A and E.
  5. Disclose the additional WHMIS E pictogram, if WHMIS pictograms are shown on the MSDS.
  6. Disclose the additional WHMIS D2 pictogram, if WHMIS pictograms are shown on the MSDS.

RN: 9092 Date: 2015-08-04

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose skin contact and eye contact as additional routes of entry.
  2. Disclose that an ingredient is corrosive.

RN: 9099 Date: 2015-09-14

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  2. Disclose that an ingredient has been shown to cause teratogenic effects.

RN: 9101 Date: 2015-07-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentration of the confidential ingredient “oxirane, polymer monoalkylether”.
  2. In relation to the first aid information shown on the MSDS for eye contact, disclose that medical attention must be obtained immediately.

RN: 9102 Date: 2015-07-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose that medical attention must be obtained immediately.

RN: 9106 Date: 2015-07-24

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentration of the ingredients in the product.
  2. Disclose that an ingredient is corrosive.

RN: 9107 Date: 2015-07-31

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose ingestion as an additional route of entry.
  2. Disclose an acceptable exposure limit for the confidential ingredient “amine compound”.

RNs: 9116 and 9117 Date: 2015-07-16

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the additional confidential ingredient “oxyalkylated resin”, and its concentration range, in the product.
  2. Disclose an LD50 (rat, oral) value of 4 000 mg/kg for the ingredient “ethylene glycol” and an LD50 (rat, oral) value of 1 220 mg/kg for the ingredient “ammonium chloride”.

RN: 9127 Date: 2015-06-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentrations of the ingredients in the product.
  2. Add “oxides of sulfur” and “hydrogen chloride” as additional hazardous combustion products.

RN: 9128 Date: 2015-06-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentrations of the ingredients in the product.

RN: 9130 Date: 2015-07-08

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LC50 (rat, vapour, 1 hour) value of 76 900 ppm for the controlled ingredient “hexane”.
  2. Disclose that the controlled ingredient “hexane” has been shown to cause mutagenic effects, in vivo.

RN: 9131 Date: 2015-08-05

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient causes mutagenic effects, in vitro.

RN: 9132 Date: 2015-08-04

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9136 Date: 2015-08-25

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause teratogenic effects in the absence of maternal toxicity in laboratory animals.

RN: 9146 Date: 2015-08-27

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.

RN: 9149 Date: 2015-09-29

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.

RN: 9158 Date: 2015-09-29

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional ingredients, along with their CAS registry numbers and their concentrations, or concentration ranges, in the product.

RN: 9171 Date: 2015-10-28

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.
  2. Disclose an LD50 (rabbit, dermal) value of 8 mL/kg for the ingredient “isopropanol”.
  3. Disclose an LD50 (rat, oral) value of 22.06 g/kg for the confidential ingredient “polyol”.
  4. Disclose that an ingredient has been shown to cause fetotoxic effects and developmental effects in the presence of maternal toxicity in laboratory animals.
  5. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9180 Date: 2015-10-30

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.
  2. Disclose an ACGIH TLV–TWA exposure limit of 10 ppm for the ingredient “diethylene glycol monobutyl ether”.
  3. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.

RN: 9185 Date: 2015-10-09

The claimant had been advised to amend the MSDS as indicated below.

  1. Add ingestion as a route of entry.
  2. Disclose an LD50 (rat, oral) value of 8 400 mg/kg for the ingredient “light aromatic naphtha”.
  3. Disclose an LD50 (rat, oral) value of 6.0 mL/kg for the ingredient “isopropanol”.
  4. Disclose an LD50 (rabbit, dermal) value of 8 mL/kg for the ingredient “isopropanol”.
  5. Disclose an LC50 (rat, vapour, 8 hours) value of 19 000 ppm for the ingredient “isopropanol”.
  6. Disclose an LD50 (rat, oral) value of 0.53 g/kg for the ingredient “2-butoxyethanol”.
  7. Disclose an LD50 (rabbit, dermal) value of 0.45 mL/kg for the ingredient “2-butoxyethanol”.
  8. Disclose an LC50 (rat, vapour, 4 hours) value of 450 ppm for the ingredient “2-butoxyethanol”.
  9. Disclose an LD50 (rat, oral) value of 12.25 mL/kg for the ingredient “methanol”.

RNs: 9199 and 9200 Date: 2015-09-17

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9201 Date: 2015-09-01

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the eyes.
  2. Disclose that an ingredient has been shown to be a skin irritant.
  3. Disclose the appropriate LD50 values (oral and dermal) and an LC50 value for the confidential ingredient “organic peroxide” in an acceptable manner.

RN: 9202 Date: 2015-10-08

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 2 100 mg/kg for the ingredient “phenol, tetrapropenyl, derivatives”.
  2. Disclose that an ingredient has been shown to cause teratogenic effects in the absence of maternal toxicity.
  3. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9203 Date: 2015-09-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that acute eye exposure to an ingredient has caused severe eye irritation in laboratory animals.
  2. Disclose that acute skin exposure to an ingredient has caused skin irritation in laboratory animals.
  3. Disclose that acute ingestion of ingredients has caused central nervous system effects in humans.
  4. Disclose that acute inhalation of an ingredient has caused toxicity in laboratory animals.
  5. Disclose the presence of an additional confidential ingredient.
  6. Disclose the presence of an additional ingredient, along with its CAS registry number.
  7. Disclose an ACGIH TLV–TWA exposure limit of 200 mg/m3 for the ingredient “kerosene”.
  8. Disclose that chronic exposure to an ingredient has caused blood effects in laboratory animals.
  9. Disclose an LD50 (rat, female, oral) value of 0.53 g/kg and an LD50 (rabbit, male, dermal) value of 0.45 mL/kg for the ingredient “2-butoxyethanol”.
  10. Disclose an LC50 (rat, female, vapour, 4 hours) value of 450 ppm for the ingredient “2-butoxyethanol”.

RN: 9205 Date: 2015-09-01

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 2 850 mg/kg for the ingredient “Bis(3-aminopropyl) ether of diethylene glycol”.
  2. Disclose that an ingredient has been shown to cause teratogenic and embryotoxic effects in the presence of maternal toxicity in laboratory animals.

RN: 9208 Date: 2015-09-16

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional confidential ingredients.
  2. Disclose an ACGIH–TLV exposure limit for the confidential ingredient “catalyst” in an acceptable manner.

RN: 9209 Date: 2015-08-26

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose eye contact as a route of entry.
  2. Disclose that an ingredient has been shown to be a skin irritant.
  3. Disclose that an ingredient has been shown to be corrosive to the eyes.

RN: 9210 Date: 2015-10-20

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9211 Date: 2015-08-28

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that the product is corrosive to the eyes.

RN: 9218 Date: 2015-09-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of nitrogen” as an additional hazardous combustion product.
  2. Disclose an LC50 (rat, vapour, 4 hours) value of >2 500 ppm for a confidential ingredient.

RN: 9220 Date: 2015-10-26

The claimant had been advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.
  2. Disclose the additional WHMIS D1 pictogram, if WHMIS pictograms are shown on the MSDS.
  3. Disclose ingestion as an additional route of entry.

RN: 9223 Date: 2015-08-13

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9225 Date: 2015-09-11

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9226 Date: 2015-08-24

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that acute ingestion of an ingredient has caused cardiopulmonary effects and kidney effects in humans.
  2. Disclose that chronic ingestion of an ingredient has caused liver effects and teratogenic/embryotoxic effects in animals in the absence of maternal toxicity.
  3. Disclose acceptable LD50 values (oral) for the ingredients in the product.
  4. Disclose an LD50 (rabbit, dermal) value of 9.53 mL/kg for the ingredient “ethylene glycol”.
  5. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

RN: 9229 Date: 2015-09-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the ACGIH “skin” notation for the ingredient “methanol”.
  2. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1B, D2A, D2B and B3.

RN: 9230 Date: 2015-09-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the ACGIH “skin” notation for the ingredient “methanol”.
  2. Disclose an LD50 (rat, oral) value of 6.7 mL/kg for the confidential ingredient “ethoxylated alcohols”.
  3. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1B, D2A, D2B and B2.

RN: 9231 Date: 2015-09-28

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an ACGIH TLV–TWA exposure limit of 250 ppm and an ACGIH TLV–STEL exposure limit of 500 ppm for the ingredient “acetone”.
  2. Disclose an LC50 (rat, vapour, 4 hours) value of 29 900 ppm for the ingredient “acetone”.
  3. Disclose that the ingredient “acetone” is toxicologically synergistic with the ingredient “acetonitrile”.

RN: 9233 Date: 2015-07-23

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9234 Date: 2015-10-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that ingestion of an ingredient has been shown to cause central nervous system effects in humans.
  2. Disclose that acute inhalation of an ingredient has caused central nervous system effects in laboratory animals.
  3. Disclose a statement to the effect that metal containers should be grounded during the transfer of large quantities of the controlled product.
  4. Disclose ingestion as an additional route of entry.
  5. Disclose an LD50 (rabbit, dermal) value of 8.00 mL/kg for the ingredient “isopropanol”.

RNs: 9239 and 9240 Date: 2015-10-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.
  2. Disclose that ingredients have been shown to cause mutagenic effects, in vitro.

RN: 9241 Date: 2015-08-07

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  2. Disclose an ACGIH TLV–C exposure limit of 100 mg/m3 for the ingredient “ethylene glycol”.
  3. Disclose an LD50 (rat, oral) value of >500 mg/kg for the confidential ingredient “alcohol ethoxylate”.
  4. Disclose an LD50 (rabbit, dermal) value of >1 000 mg/kg for the confidential ingredient “alcohol ethoxylate”.
  5. Disclose that an ingredient has been shown to cause teratogenic and fetotoxic effects.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9242 Date: 2015-10-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.
  2. Disclose that ingredients in the product have been shown to cause mutagenic effects, in vitro.

RN: 9243 Date: 2015-10-02

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, female, oral) of >500 mg/kg for the confidential ingredient “alkylalkoxysilane”.

RN: 9244 Date: 2015-08-06

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause central nervous system effects in humans.
  2. Disclose an acceptable exposure limit for the confidential ingredient “aliphatic alcohol B”.
  3. Disclose that an ingredient has been shown to cause teratogenic effects.
  4. Disclose that an ingredient has been shown to cause chronic effects on the male reproductive function in laboratory animals.
  5. Disclose an LD50 (rat, oral) value of >5 000 mg/kg for the confidential ingredient “aliphatic alcohol B”.
  6. Disclose an LC50 (rat, vapour, 4 hours) value of >100 mg/L for the confidential ingredient “aliphatic alcohol B”.
  7. Disclose an LD50 (rabbit, dermal) value of 6 280 mg/kg for the confidential ingredient “substituted alcohol” and an LD50 (rabbit, dermal) value of >3 000 mg/kg for the confidential ingredient “aliphatic alcohol A”.

RN: 9260 Date: 2015-08-26

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 2.46 mL/kg for the ingredient “2-ethylhexanol”.
  2. Disclose an LD50 (rabbit, dermal) value of 3.56 mL/kg for the ingredient “methyl isobutyl carbinol”.
  3. Disclose that an ingredient is a skin irritant.

RN: 9329 Date: 2015-07-10

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be an eye irritant.
  2. Disclose an LD50 (rat, oral) value of >500 mg/kg for the confidential ingredients “alcohol ethoxylate 1”, “alcohol ethoxylate 2”, “alcohol ethoxylate 3”, “alcohol ethoxylate 4” and “alcohol ethoxylate 5”.
  3. Disclose an LD50 (rabbit, dermal) value of >1 000 mg/kg for the confidential ingredients “alcohol ethoxylate 1” and “alcohol ethoxylate 3” and an LD50 (rabbit, dermal) value of >200–1 000 mg/kg for the confidential ingredient “alcohol ethoxylate 2”.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

RNs: 9367 and 9368 Date: 2015-07-07

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RNs: 9369, 9370 and 9371 Date: 2015-07-07

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9373 Date: 2015-08-11

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.
  2. Disclose the presence of an additional ingredient, along with its concentration, or concentration range, in the product.
  3. Disclose an LD50 (rat, oral) value of 2 850 mg/kg for the ingredient “Bis(3-aminopropyl) ether of diethylene glycol”.
  4. Disclose an LD50 (rat, oral) value of 625 mg/kg and an LD50 (rabbit, dermal) value of 2 110 mg/kg for the ingredient “methylenedi(cyclohexylamine)”.
  5. Disclose an LD50 (rat, oral) value of 368 mg/kg for the confidential ingredient “polyamide resin”.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

RN: 9377 Date: 2015-07-29

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9378 Date: 2015-07-03

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 4.00 g/kg for the ingredient “ethylene glycol”.

RN: 9379 Date: 2015-07-13

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 4 g/kg for the ingredient “ethylene glycol”.
  2. Disclose an LD50 (rabbit, dermal) value of 0.635 mL/kg for the ingredient “tetrakis(hydroxymethyl)phosphonium sulfate”.
  3. Disclose an LC50 (rat, aerosol, 4 hours) value of 0.591 mg/L for the ingredient “tetrakis(hydroxymethyl)phosphonium sulfate”.
  4. Disclose that an ingredient has been shown to cause teratogenic effects in the presence of maternal toxicity in laboratory animals.
  5. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.

RN: 9380 Date: 2015-09-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9382 Date: 2015-06-15

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 583 mg/kg for the confidential ingredient “xanthate derivate” and an LD50 (rat, oral) value of 586 mg/kg for the confidential ingredient “aminothioate derivate”.

RN: 9383 Date: 2015-06-15

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the additional WHMIS D2B pictogram if WHMIS pictograms are shown on the MSDS.
  2. Disclose an ACGIH–TLV ceiling value of 2 mg/m3 for the ingredient “sodium hydroxide”.
  3. Disclose an LD50 (rat, oral) value of 586 mg/kg for the confidential ingredient “aminothioate derivative”.

RN: 9384 Date: 2015-08-24

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an ACGIH TLV–TWA exposure limit of 50 ppm for the ingredient “isobutyl alcohol”.
  2. Disclose the acceptable LD50 values for the confidential ingredients “aminothioate derivative” and “xanthane derivative”.

RNs: 9385, 9386, 9388, 9389 and 9390 Date: 2015-08-04

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9387 Date: 2015-08-12

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9391 Date: 2015-09-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9392 Date: 2015-09-10

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 1 710 mg/kg for the ingredient “zinc sulfate”.

RN: 9393 Date: 2015-08-24

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.
  2. Disclose an ACGIH TLV–TWA exposure limit of 0.01 ppm for the ingredient “potassium iodide”.
  3. Disclose the acceptable LD50 value for the confidential ingredient “propargyl alcohol derivative”.
  4. Disclose that an ingredient has been shown to cause teratogenic and embryotoxic effects in the absence of maternal toxicity in laboratory animals.

RN: 9394 Date: 2015-08-11

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of >50–500 mg/kg for the confidential ingredient “amine”.
  2. Disclose that chronic ingestion of an ingredient caused liver effects in laboratory animals.
  3. Disclose that an ingredient has been shown to cause mutagenic effects.

RN: 9395 Date: 2015-08-11

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LC50 (rat, vapour, 4 hours) value of 2 620 ppm for the confidential ingredient “hydroxyl amine”.
  2. Disclose an acceptable ACGIH–TWA exposure limit for the confidential ingredient “hydroxyl amine”.
  3. Disclose that chronic ingestion of an ingredient in the product has caused liver effects in laboratory animals.
  4. Disclose that an ingredient has been shown to cause mutagenic effects.

RN: 9397 Date: 2015-08-14

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.

RN: 9404 Date: 2015-07-28

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  2. Disclose an LD50 (rabbit, dermal) value of >5 000 mg/kg for the confidential ingredient “alcohol”.
  3. Disclose an LD50 (rabbit, dermal) value of >5 000 mg/kg for the confidential ingredient “polyol”.
  4. Disclose that an ingredient has been shown to cause teratogenic and embryotoxic effects.

RN: 9405 Date: 2015-08-26

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  2. Disclose that an ingredient has been shown to cause respiratory sensitization in laboratory animals.

RN: 9406 Date: 2015-07-07

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the skin.
  2. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.

RN: 9407 Date: 2015-08-04

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9410 Date: 2015-09-28

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 1 560 mg/kg for the confidential ingredient “phosphorous acid”.
  2. Disclose that an ingredient causes skin sensitization and has been shown to be corrosive to the skin.

RN: 9411 Date: 2015-07-15

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9412 Date: 2015-08-19

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 2 910 mg/kg for the ingredient “butylated hydroxyanisole (BHA)”.

RN: 9414 Date: 2015-10-02

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  2. Disclose an LD50 (rat, oral) value of >50–500 mg/kg for the confidential ingredient “alkylene amine”.
  3. Disclose an LD50 (rabbit, dermal) value of >200–1 000 mg/kg for the confidential ingredient “alkylene amine”.
  4. Disclose an LD50 (rabbit, dermal) value of >1 000 mg/kg for the confidential ingredient “alkanolamine”.
  5. Disclose an LD50 (rat, oral) value of 5 660 mg/kg for an additional ingredient.
  6. Disclose an LD50 (rabbit, dermal) value of 1.23 mL/kg for an additional ingredient.
  7. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.
  8. Disclose the additional WHMIS D1 pictogram if WHMIS pictograms are shown on the MSDS.

RN: 9418 Date: 2015-09-14

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be an eye irritant.
  2. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  3. In relation to the first aid information shown on the MSDS for eye contact, disclose an appropriate flush time and that medical attention must be obtained immediately.
  4. Disclose an ACGIH ceiling value of 100 mg/m3 (aerosol only) for the ingredient “ethylene glycol”.
  5. Disclose an LD50 (rat, oral) value of 2.9 g/kg for the ingredient “zinc alkyl dithiophosphate” and an LD50 (rat, oral) value of 2 100 mg/kg for the ingredient “branched alkylphenol”.
  6. Disclose that an ingredient has been shown to cause fetotoxic effects and teratogenic effects in the absence of maternal toxicity in laboratory animals.
  7. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9422 Date: 2015-08-13

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 30 g/kg for the confidential ingredient “phenolic epoxy resin # 1”.
  2. Disclose an LD50 (rabbit, dermal) value of >1 000–2 000 mg/kg for the confidential ingredient “aliphatic glycidyl ether”.

RN: 9423 Date: 2015-09-17

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the acceptable LD50 (rat, oral) values for the ingredients “diacetone alcohol” and “phenolic epoxy resin #1”.

RN: 9434 Date: 2015-09-28

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, along with its concentration, or concentration range, in the product.
  2. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2B.

RN: 9465 Date: 2015-09-29

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed.

RN: 9469 Date: 2015-09-24

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2B.
  2. Disclose that an ingredient has been shown to be a skin irritant.
  3. Disclose the presence of an additional confidential ingredient.
  4. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.
  5. Disclose an LD50 (rabbit, dermal) value of 2.14 mL/kg for the confidential ingredient “ethoxylated alcohols”.

RN: 9504 Date: 2015-09-22

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed.
  2. Disclose an LD50 (rat, dermal) value of >500 mg/kg for the confidential ingredient “substituted phenol 4”.
  3. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “substituted phenol 4”.
CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended MSDS to the screening officer within 30 days of expiry of the appeal period.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the MSDS reviewed by the screening officer and the date of the order.

RN: 9055 Date: 2015-08-19

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

1. Disclose the concentrations of the ingredients in the product.

2. Disclose an ACGIH TLV–TWA exposure limit of 10 ppm for the confidential ingredient “glycol ether”.

RN: 9206 Date: 2015-10-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

1. Disclose the chemical identity, CAS registry number and concentration, or concentration range, of an ingredient.

RN: 9451 Date: 2015-10-15

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

1. Disclose that an ingredient has been shown to be corrosive to the eyes.

CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED THE DECISION THAT THE CLAIM FOR EXEMPTION WAS EITHER PARTIALLY VALID OR INVALID

In the case of the following claims, the screening officer issued the decision that the claims for exemption were partially valid.

Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an MSDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant MSDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 9054

Date of order: 2015-08-19

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the concentrations of the ingredients in the product.
  2. Disclose an LD50 (rabbit, dermal) value of 2.3 g/kg for the confidential ingredient “alkoxylated long chain alkyl alcohol”.

RN: 9056

Date of order: 2015-10-29

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9070

Date of compliance undertaking: 2015-07-17

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  2. Disclose an ACGIH TLV–TWA exposure limit of 2 mg/m3 and an ACGIH TLV–STEL exposure limit of 6 mg/m3 for the confidential ingredient “complex mineral”.
  3. Disclose that ingredients have been shown to cause teratogenic effects and reproductive toxicity in laboratory animals.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9080

Date of compliance undertaking: 2015-07-16

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause teratogenic effects.

RN: 9140

Date of order: 2015-06-01

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number.

RN: 9189

Date of compliance undertaking: 2015-09-28

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the eyes.
  2. Disclose that an ingredient has been shown to cause skin sensitization in laboratory animals.
  3. Disclose an LD50 (rat, oral) value of 1 440 mg/kg for the confidential ingredient “phosphonic acid derivative”.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class E.

RN: 9213

Date of compliance undertaking: 2015-08-13

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the eyes.

RN: 9219

Date of compliance undertaking: 2015-08-04

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose inhalation as a route of entry.
  2. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  3. Disclose concentration ranges for the confidential ingredients “siloxane polyalkyleneoxide copolymer” and “polyalkylene oxide”.
  4. Disclose that ingredients have been shown to cause reproductive toxicity in laboratory animals.

RN: 9246

Date of compliance undertaking: 2015-08-20

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in laboratory animals.

RN: 9309

Date of compliance undertaking: 2015-09-29

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of five additional confidential ingredients, along with their CAS registry numbers and their concentrations, or concentration ranges, in the product.
  2. Disclose that an ingredient has been shown to cause skin sensitization in laboratory animals.

RN: 9364

Date of compliance undertaking: 2015-08-27

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9366

Date of compliance undertaking: 2015-07-17

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of three additional confidential ingredients.
  2. Disclose an LD50 (rat, oral) of 2 551 mg/kg for the confidential ingredient “petroleum distillates”.

RN: 9374

Date of compliance undertaking: 2015-09-30

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional confidential ingredients.

RN: 9400

Date of compliance undertaking: 2015-08-11

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rat, oral) value of 2 551 mg/kg for the confidential ingredient “petroleum distillates (I)”.

RN: 9401

Date of compliance undertaking: 2015-10-02

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient.
  2. Disclose that ingredients have been shown to be eye irritants.
  3. Disclose an LD50 (rat, oral) value of 1.26 g/kg for the confidential ingredient “sodium petroleum sulfonates (I)”.

RN: 9421

Date of compliance undertaking: 2015-08-17

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in laboratory animals.

RN: 9505

Date of order: 2015-09-18

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number.

In the case of the following claim, the screening officer issued the decision that the claim for exemption was invalid.

Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an MSDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant MSDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 9137

Date of compliance undertaking: 2015-08-28

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (rabbit, dermal) value of 57 mg/kg for the ingredient “chromium (VI) trioxide”.
  2. Disclose an LC50 (rat, aerosol, 4 hours) value of 167 mg/m3 for the ingredient “chromium (VI) trioxide”.
  3. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1A, D2A and E.
CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED A DECISION ON THE CLAIM FOR EXEMPTION BUT WHICH WERE DISCONTINUED PRIOR TO THE ISSUANCE OF EITHER A SIGNED UNDERTAKING OR SIGNED ORDERS

The screening officer has identified the following instances of non-compliance with the requirements of the relevant legislation.

RN: 9057

Date of statement of decisions: 2015-06-11

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LC50 (rat, dust, 4 hours) value of <1.17 mg/L and >0.27 mg/L for the ingredient “sodium dichloro-S-triazinetrione”.

RN: 9152

Date of statement of decisions: 2015-06-26

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause mutagenic effects.

RN: 9193

Date of statement of decisions: 2015-08-24

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin corrosion in laboratory animals.
  2. Disclose that an ingredient has been shown to cause eye corrosion in laboratory animals.
  3. Disclose that an ingredient has been shown to cause skin sensitization in laboratory animals.
  4. Disclose an LD50 (rabbit, dermal) value of 1.25 mL/kg for a confidential ingredient.
  5. Disclose an LD50 (rat, oral) value of 1 400 mg/kg for a confidential ingredient.
  6. Disclose an LD50 (rat, oral) value of 2 710 mg/kg for a confidential ingredient.
  7. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class E.

RN: 9398

Date of statement of decisions: 2015-06-30

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9399

Date of statement of decisions: 2015-06-30

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9467

Date of statement of decisions: 2015-08-25

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.

[3-1-o]